Abstract
Growing evidence supports the notion that pharmaceutical targeting of the 5-hydroxytryptamine (5-HT) and dopamine (DA) systems offers the potential to treat human immune system disorders. This review describes this emerging area of research, which has the benefit of being supported by a relatively detailed understanding of these monoamine systems within other tissues of the body. Furthermore, the availability of a number of pharmaceutical agents originally developed to manipulate central monoamine function, offer many suitable drug candidates to test their therapeutic potential in the immune pathology arena.
| Original language | English |
|---|---|
| Pages (from-to) | 218-25 |
| Number of pages | 8 |
| Journal | Seminars in Cancer Biology |
| Volume | 18 |
| DOIs | |
| Publication status | Published - 1 Jun 2008 |
Keywords
- serotonin
- dopamine
- novel drug targets
- lymphoma
- drug reprofiling